NewsRoom Articles - Page 50 of 144 - PsychedelicNewsWire (PNW)

FridayApr 29, 2022 9:00 am

Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) Driving the Psychedelic Conversation Forward Through Education, Research, and Service Delivery

Delic is committed to bringing science-backed benefits to as many people as possible while also changing the narrative around psychedelics It seeks to achieve this through education, products and services, and research on psychedelics So far, LSD and psilocybin have proven to reduce end of life (“EOL”) anxiety for terminally ill patients Delic recognizes the potential of psychedelics and their application in therapeutics, hence its investment in research, civic education, and service delivery in this sector For many years, psychedelic drugs were frowned upon by society. This, along with psychedelics’ widespread popularity as recreational drugs in the 1960s and 70s,…

ThursdayApr 28, 2022 2:25 pm

Advocates Urge Use of Alternative Treatments to Curb Veteran Suicides

Recently released federal data shows that in the state of Texas, approximately 10 veterans are taking their lives every week. Various veterans’ organizations and advocates are calling for the state government to find alternative ways, such as psychedelics, to tackle this issue. In an interview, Navy veteran Marcus Capone revealed that he’d been diagnosed with depression after leaving the military. Capone, who is cofounder of the VETS not-for-profit organization, explained that he turned to psychedelic drugs after current treatments proved to be ineffective. The VETS nonprofit was established to allocate funding for psychedelic therapy and help run as well as…

ThursdayApr 28, 2022 9:30 am

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Releases Preclinical Data from CYB004 Study Showing Significant Advantages

Earlier studies show that CYB004 via inhalation may solve existing challenges and support a clinical path forward for this important therapeutic Cybin is currently developing CYB004 for the treatment of anxiety disorders The new chemical entity is covered by a patent issued earlier this year Cybin (NEO: CYBN) (NYSE American: CYBN) has released data from a pharmacokinetic study focused on evaluating CYB004, the company’s proprietary deuterated dimethyltryptamine (“DMT”) molecule (https://ibn.fm/nyCj8). The study analyzed delivery methods of CYB004, and showed initial data indicates significant advantages over Intravenous (“IV”) and Inhaled DMT. "In many studies, DMT has shown to be a promising and…

WednesdayApr 27, 2022 1:03 pm

Risks Prospective Psychedelic Investors Need to Consider

Various studies have found that psychedelic treatments have the potential to treat mental health conditions such as anxiety and depression, among others. This, coupled with the ineffectiveness of current treatments, has made investing in psychedelics appear even more lucrative. However, before rushing to invest in this burgeoning industry, there are a couple of things that one should consider before purchasing psychedelic stocks. We discuss them below. Competitiveness of the market This may be the biggest risk to investors of psychedelic stocks. Currently, more than 50 publicly trading firms are working with psychedelics, including DMT, LSD, MDMA and psilocybin. While there…

WednesdayApr 27, 2022 9:00 am

Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) Moves to Become the Go-To Provider of Psychedelic Medicine Treatment as it Seeks Approval of Additional Compounds

Delic is a leader in new medicines and treatments that offers education, research, high-quality products, and treatment options The company is on a mission to help heal the mental health pandemic, which has been triggered and worsened by the COVID-19 disease Delic operates the largest, most profitable chain of wellness clinics providing ketamine treatments in the United States With 13 clinics already in operation, Delic is eyeing expansion as it seeks to ensure 60-70% of Americans are within a 45-minute drive to its clinics The latest data from the World Health Organization (“WHO”) shows that the COVID-19 pandemic has triggered…

TuesdayApr 26, 2022 2:42 pm

Study Finds That Psychedelics Free Up Brains of Individuals with Depression

New research has discovered that psilocybin may free up the brains of individuals suffering from depression more effectively, in comparison to antidepressants. Psilocybin is the active hallucinogenic compound found in magic mushrooms, and it belongs to a class of drugs known as psychedelics. Psychedelic substances usually affect an individual’s senses, altering their emotions and perception of time as well as their thinking. Psychedelics such as LSD, psilocybin and MDMA are currently being studied for use in treating various mental health conditions. This particular study’s results show that these substances could help treat severe depression. However, the researchers warn against consuming…

MondayApr 25, 2022 1:00 pm

Three Kinds of Trauma Psychedelics Hope to Treat

Currently, there are a number of ongoing and planned clinical trials looking into the use of psychedelic therapies in the treatment of post-traumatic stress disorder (PTSD). Most of these trials focus on one particular psychedelic, MDMA, which is commonly known as ecstasy. However, other psychedelic compounds have also shown therapeutic potential, especially with regard to treating trauma. Given that trauma comes in different forms, researchers are focused on addressing the primary/root causes of trauma using psychedelics. Here we discuss broad categorizations of trauma being targeted by psychedelics. Trauma and sexual and emotional abuse Research has found that psychedelics may be…

MondayApr 25, 2022 9:30 am

Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) Continues Investor Outreach as Psychedelic Wellness Drug Development Advances

Delic Holdings Corp operates in North America to advance the use of psychedelics in treating difficult conditions related to major depression, PTSD and anxiety The company has a three-pronged approach to promoting access and affordability for treatment drugs: conducting research in its lab facility, advancing treatment through its clinical network, and educating the public through conferences and Web-based media The use of psychedelic drugs to treat these mental health concerns is gaining credibility some 50 years after hallucinogenic drugs reached their peak use and were generally declared illegal Delic recently received Health Canada authorization to obtain 60 grams of psilocybin…

FridayApr 22, 2022 11:47 am

GoDaddy Billionaire Owner Supports Use of Psychedelics as Treatment for PTSD

Over the past couple of years, there has been increased interest in psychedelics as alternative treatments for mental disorders. With most mental health medications causing side effects such as muscle spasms, nausea, constipation and loss of sex drive, there has been a push for safer alternative medications. Studies show that psychedelics have the potential to treat mental disorders, including post-traumatic stress disorder (PTSD), major depressive disorder, anorexia nervosa and alcohol-use disorder. Mental health conditions take nearly 8 million lives every year and cost the world billions of dollars in lost productivity. According to the National Institute of Mental Health (NIMH),…

ThursdayApr 21, 2022 3:07 pm

Why MindMed’s LSD Trial for Anxiety May Be Important to Psychedelic Investors

Mind Medicine Inc. (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ) is set to present preliminary topline effectiveness and safety results from its phase IIa study, which involves the treatment of anxiety disorder using LSD in conjunction with therapy. Many, including investors, expect the trial’s results to be a turning point for the company. LSD (lysergic acid diethylamide) is a potent hallucinogen that is synthetically manufactured from lysergic acid. It’s commonly known as acid, mellow yellow, doses and trips. When ingested in small doses, this hallucinogen produces mild changes in mood, thought and perception. The company has many projects using LSD, including…

News and publishing service for psychedelic related companies

Contact us: 415.949.5050